Lv2
140 积分 2024-10-12 加入
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
2天前
已完结
AML treatment: conventional chemotherapy and emerging novel agents
2天前
已完结
Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations
3个月前
已完结
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study
3个月前
已完结
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
3个月前
已完结
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment
3个月前
已完结
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
4个月前
已完结
Response and Resistance to Menin Inhibitor in UBTF-Tandem Duplication AML
4个月前
已完结
Menin inhibitors in the treatment of acute myeloid leukemia
4个月前
已关闭
皖公网安备34019202002308
